News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
JPMorgan Chase & Co. has reduced its price target for Oculis (NASDAQ:OCS) to $20.00 from $23.00, while maintaining an "overweight" rating. Despite this reduction and similar cuts by other firms, Oculis still holds a consensus "Moderate Buy" rating with an average price target of …
This article provides detailed financial and analytical data for Ocular Therapeutix Inc (OCUL), including its live stock price, chart, news, and a comprehensive stock score. It covers key financial figures, performance over various periods, technical analysis, analyst ratings, and company profile. The data shows …
Stifel has reiterated a Buy rating and a $40 price target for Oculis Holding AG (NASDAQ:OCS), based on discussions about its lead asset, privosegtor. Despite a recent stock drop and an "overvalued" assessment by InvestingPro, analysts maintain a strong buy consensus. Oculis is shifting …
Shares of Oculis Holding AG (OCS) have recently gained 1.7%, and Wall Street analysts project a potential rally of 187.83%, with a mean estimate of $36.9. Despite the inherent skepticism surrounding analyst price targets, a strong agreement among analysts on OCS's earnings potential and …
Zacks Research upgraded Ocular Therapeutix (NASDAQ:OCUL) from a "strong sell" to a "hold" rating. Despite this change, the consensus among analysts remains a "Moderate Buy" with an average price target of $25.75, reflecting broad positive sentiment. The company recently reported better-than-expected quarterly results, with …
Ocular Therapeutix, Inc. announced inducement grants to Ms. Beth Rada, the new SVP of Government Affairs and Public Policy. These awards, consisting of stock options and restricted stock units, were granted under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule …
Ocular Therapeutix (NASDAQ: OCUL) has granted its new SVP, Government Affairs and Public Policy, Beth Rada, inducement equity awards under its 2019 Inducement Stock Incentive Plan. These awards, effective August 10, 2026, include a non-statutory option to purchase up to 85,000 shares at $9.24 …
Ocular Therapeutix (OCUL) is under investor scrutiny following wider quarterly losses and a new shelf registration filing, which could lead to future stock dilution. Despite a recent share price rebound, the stock remains down year-to-date. The company's valuation is heavily tied to the potential …
HC Wainwright has lowered its Q3 2026 EPS estimate for Oculis (NASDAQ: OCS) to a loss of $0.48 per share, maintaining a "Buy" rating and a $26 price target. Oculis previously reported a Q2 loss of $0.20 per share with $0.38 million in revenue …
Dimensional Fund Advisors LP has initiated a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL), purchasing 649,756 shares valued at approximately $5.49 million. This move is part of broader institutional interest, with hedge funds and other institutional investors collectively owning 59.21% of the biopharmaceutical company's …
Oculis Holding AG has acquired all worldwide development and commercial rights to Privosegtor and ACT-02 from Accure Therapeutics for $3.8 million cash and up to 2,050,000 Oculis shares. This acquisition follows Oculis's Phase III OCS-01 failure and aims to consolidate its pipeline around these …
Janus Henderson Group PLC significantly reduced its stake in Ocular Therapeutix by 98.4% in the first quarter, now holding 68,500 shares valued at $581,000. Despite this, institutional investors collectively own 59.21% of the company. Ocular Therapeutix reported better-than-expected Q1 earnings, with a loss of …
Oculis Holding AG has announced an asset purchase agreement with Accure Therapeutics to acquire global rights to Privosegtor, a neuroprotective drug candidate, for an upfront payment of $3.8 million and up to 2,050,000 Oculis ordinary shares. This strategic move follows the failure of Oculis's …
The Manufacturers Life Insurance Company significantly increased its stake in Ocular Therapeutix (NASDAQ:OCUL) by 145.9% in the first quarter, now owning 227,808 shares. This acquisition is part of a broader trend of institutional investment, with hedge funds and institutional investors collectively owning 59.21% of …
Oculis Holding AG has agreed to acquire full development and commercial rights to Privosegtor (ACT-01) and preclinical candidate ACT-02 from Accure Therapeutics for an upfront cash payment of $3.8 million and up to 2,050,000 Oculis ordinary shares. This deal terminates a prior licensing agreement, …
Oculis Holding AG announced a strategic asset purchase agreement to acquire the global development and commercial rights to Privosegtor and future candidate ACT-02 from Accure Therapeutics. This deal, valued at $3.8 million upfront cash and up to 2,050,000 Oculis ordinary shares, terminates their previous …
Oculis Holding AG has acquired all worldwide rights to Privosegtor from Accure Therapeutics for an upfront cash payment of $3.8 million and up to 2,050,000 Oculis shares, with the deal expected to close by early 2027. This acquisition ends their previous license agreement and …
ZUG, Sviss og BARSELÓNA, Spáni, ágúst 10, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” eða “félagið”), alþjóðlegt líftæknifyrirtæki með áherslu á nýsköpun til að mæta brýnni þörf fyrir meðferðir við augnsjúkdómum og augntaugasjúkdómum, og Accure Therapeutics, S.L. (“Accure”), rannsóknar- og …
ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a …
This article provides comprehensive financial information for Oculis Holding AG (OCS), including its current stock price, historical data, and key financial metrics. It highlights the company's focus on developing drug candidates for ophthalmic, neuro-ophthalmic, and neurological diseases, with lead products in various clinical trial …
Ocular Therapeutix (OCUL) reported flat Q2 2026 revenue of US$13.48 million and a widened net loss of US$78.76 million. Coinciding with these results, the company filed an US$81.7 million shelf registration for up to 10 million shares, indicating a strategic move to maintain funding …
Ocular Therapeutix (OCUL) shares rose 5% ahead of its Investor Day, driven by the announcement of its regulatory strategy for Axpaxli, an experimental wet age-related macular degeneration (AMD) therapy. The company plans to submit its New Drug Application (NDA) in Q4 2026, supported by …
Ocular Therapeutix (NASDAQ:OCUL) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen. The company reported quarterly revenue of $13.47 million and an adjusted loss of $0.35 per share, exceeding analyst estimates. Despite the upgrade, other analysts maintain a "Moderate …
Analysts have lowered the 12-month average price target for Oculis Holding AG stock (OCS) to $36.26 from $36.49, with a range of $22.25 to $43.27. Despite the slight reduction, this new target still suggests a significant 193% potential upside from its Aug. 6 closing …
Ocular Therapeutix (NASDAQ: OCUL) has granted inducement equity awards to eight new non-executive employees, including stock options for up to 53,975 shares and restricted stock units for 17,450 shares, effective August 3, 2026. The stock options have an exercise price of $8.40 per share, …
Oculis Holding reported second-quarter earnings that surpassed analyst estimates by CHF0.23, with revenue also exceeding expectations at CHF311.14K against a consensus of CHF157.82K. Despite the positive earnings surprise, the company's stock price has seen a significant decline, down -62.070% in the last 3 months …
Oculis Holding AG (OCS) reported a narrower-than-expected Q2 loss of $0.2 per share, beating the Zacks Consensus Estimate of a $0.48 loss, and surpassed revenue estimates with $0.39 million. Despite this, the company's shares have fallen 39.6% year-to-date, contrasting with the S&P 500's gain, …
ZUG, Sviss, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Félagið færir nú áherslur sínar yfir á taugaauknlækningar með Privosegtor sem leiðandi þróunarlyf félagsins á síðari stigum klínískrar þróunar í gegnum PIONEER-áætlunina. Í kjölfar jákvæðs pre-IND fundar við Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA), eru möguleikar á …
Oculis, a global biopharmaceutical company, announced its Q2 2026 financial results, reporting $282.3 million in cash, cash equivalents, and short-term investments, providing a cash runway into the second half of 2029. The company is advancing its neuro-ophthalmology pivot with Privosegtor as a lead late-stage …
Ocular Therapeutix (NASDAQ:OCUL) recently released strong second-quarter results, beating revenue expectations and posting smaller-than-anticipated statutory losses. Analysts have slightly increased their optimism regarding per-share losses for 2026, though revenue forecasts remain unchanged. Despite this, the consensus price target of US$27.09 has not shifted, and …
Oculis Holding Ag (OCS) shows divergent sentiment across different time horizons, suggesting choppy conditions with elevated downside risk. The article provides institutional trading strategies including long, momentum breakout, and short strategies, along with a multi-timeframe signal analysis detailing support and resistance levels. It emphasizes …
Search by ticker symbol or company name and select a result to open its chart.